Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03831711 · ClinicalTrials.gov registry record · Phase 1
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
A Phase 1 study, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03831711 is a Phase 1 study that has completed, run by Andrei Iagaru. The registered enrollment target is 5 participants.
The verdict
NCT03831711, a Phase 1 study, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- DRUG Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
- DEVICE Investigational software and coils in PET/MR scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03831711
The ClinicalTrials.gov registry entry for NCT03831711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT03831711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03831711 about?
NCT03831711 is a clinical study titled "68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer". This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
What is the current status of trial NCT03831711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-03-19. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT03831711?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Gallium Ga 68-labeled GRPR Antagonist BAY86-7548 (DRUG), Investigational software and coils in PET/MR scan (DEVICE).
Who is sponsoring clinical trial NCT03831711?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.